NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SELENOMETHIONINE SE-75 is an injectable radiopharmaceutical containing selenium-75, a radioactive tracer used for diagnostic imaging. The product is sponsored by PharmaLundensis and remains in pre-launch stage with an NDA type designation. Specific therapeutic indications and mechanism of action are not currently disclosed in available data.
Pre-Launch
As a pre-launch radiopharmaceutical, this product presents early-stage opportunity for regulatory, medical affairs, and commercial planning teams at PharmaLundensis.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SELENOMETHIONINE SE-75 offers early-career exposure to radiopharmaceutical development and pre-launch commercialization at a specialized company. Team size and hiring activity are currently minimal, but growth may accelerate upon regulatory approval and market entry.
Regulatory Affairs SpecialistMedical Affairs Manager
Worked on SELENOMETHIONINE SE 75 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.